Evidence map›Paper›PMID 34851401›Full record

Trial reportJAMA network open2021

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.

Kyla A McKay, Fredrik Piehl, Simon Englund, Anna He, Annette Langer-Gould, Jan Hillert, Thomas Frisell

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kyla A McKayNeuro Division, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Fredrik PiehlNeuro Division, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Simon EnglundClinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Anna HeNeuro Division, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Annette Langer-GouldDepartment of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles.
Jan HillertNeuro Division, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Thomas FrisellClinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HospitalizationSeverity of Illness IndexAdultCase-Control StudiesDrug Administration ScheduleFemaleHumansImmunologic FactorsMaleMiddle AgedMultiple SclerosisRituximabSARS-CoV-2SwedenImmunologic FactorsRituximab

Identifiers

PMID34851401
PMCPMC8637249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.